Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies

F Song, R Fux, LB Provacia, A Volz, M Eickmann, S Becker, Ab Osterhaus, Bart Haagmans, G Sutter

Research output: Contribution to journalArticleAcademicpeer-review

122 Citations (Scopus)


Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.
Original languageUndefined/Unknown
Pages (from-to)11950-11954
Number of pages5
JournalJournal of Virology
Issue number21
Publication statusPublished - 2013

Research programs

  • EMC MM-04-27-01

Cite this